Sterling, Virginia-based biotech company Aperiomics closed an additional $1.2 million in Series A funding, to close the round at $3 million. The company announced the first $1.8 million in Series A funding in August 2019.

Founded in 2014, the company uses genomic analysis to detect every known pathogen from a sample of any nature in just one test. Aperiomics also launched a test quickly back in March that could detect COVID-19.

This latest Series A funding round was led by VentureSouth and includes investments from Pipeline Angels, Atlanta Technology Angels, The Launch Place and the Central Texas Angel Network. With the official close of its Series A, Aperiomics is also raising a $1 million bridge note to help fund the company until it closes a Series B. The bridge note lead investor, Tamiami Angel Fund IV, has already invested $300,000, and Aperiomics reports that investments from its executives will be included in this note.

READ FULL ARTICLE HERE